On or around 05/14/2019 (Notice of voluntarily dismissal)
Filing Date: March 22, 2019
According to the Complaint, Osiris researches, develops, manufactures and commercializes regenerative medicine products.
On March 12, 2019, Osiris issued a press release announcing the Proposed Transaction. Pursuant to the Merger Agreement: (i) Papyrus Acquisition Corp. will merge with and into Osiris, and (ii) Osiris shall continue as the surviving corporation in the Merger.
The Complaint alleges that the Defendants misrepresented or omitted material information concerning the Proposed Transaction in the Proxy, in violation of Section 14(d) of the Exchange Act.
This case was voluntarily dismissed as moot on May 14, 2019.
Company & Securities Information
Defendant: Osiris Therapeutics, Inc.
Industry: Biotechnology & Drugs
Headquarters: United States
Ticker Symbol: OSIR
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Elizabeth A. Recupero, et al. v. Peter Friedli, et al.